BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

728 related articles for article (PubMed ID: 16865268)

  • 1. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique.
    Imura K; Ueda Y; Hayashi T; Itoh T; Shimizu K; Tamai H; Yano Y; Naito K; Kohara J; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H
    Int J Oncol; 2006 Sep; 29(3):531-9. PubMed ID: 16865268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunogenic reactivity of CTLs induced by electrofusion cells of human dendritic cells and gastric cancer cells].
    Imura K; Hayashi T; Yano Y; Naito K; Kouhara J; Ueda Y; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1797-9. PubMed ID: 15553719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma.
    Yasuda T; Kamigaki T; Kawasaki K; Nakamura T; Yamamoto M; Kanemitsu K; Takase S; Kuroda D; Kim Y; Ajiki T; Kuroda Y
    Cancer Immunol Immunother; 2007 Jul; 56(7):1025-36. PubMed ID: 17131118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro.
    Zhou Q; Guo AL; Xu CR; An SJ; Wang Z; Yang SQ; Wu YL
    Clin Exp Immunol; 2008 Sep; 153(3):392-400. PubMed ID: 18803763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
    Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
    Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes.
    Tanaka F; Yamaguchi H; Haraguchi N; Mashino K; Ohta M; Inoue H; Mori M
    Int J Oncol; 2006 Nov; 29(5):1263-8. PubMed ID: 17016660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells.
    Zhang Y; Ma B; Zhou Y; Zhang M; Qiu X; Sui Y; Zhang X; Ma B; Fan Q
    Breast Cancer Res Treat; 2007 Nov; 105(3):277-86. PubMed ID: 17187233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo host response to gastrointestinal cancer cells presented by autologous dendritic cells.
    Galetto A; Contarini M; Sapino A; Cassoni P; Consalvo E; Forno S; Pezzi C; Barnaba V; Mussa A; Matera L
    J Surg Res; 2001 Sep; 100(1):32-8. PubMed ID: 11516202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antitumor efficacy of fusion cells from esophageal carcinoma cells and dendritic cells as a vaccine in vitro].
    Deng YJ; Xia JC; Zhou J; Wang QJ; Zhang PY; Zhang LJ; Rong TH
    Ai Zheng; 2007 Feb; 26(2):137-41. PubMed ID: 17298741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous high-killing cytotoxic T lymphocytes against human lung cancer are induced using interleukin (IL)-1beta, IL-2, IL-4, and IL-6: possible involvement of dendritic cells.
    Saijo Y; Hong X; Tanaka M; Tazawa R; Liu SQ; Saijo K; Ohno T; Koike K; Ohkuda K; Satoh K; Nukiwa T
    Clin Cancer Res; 1999 May; 5(5):1203-9. PubMed ID: 10353758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Killing activity of cytotoxic T lymphocytes stimulated by dendritic cell vaccine loaded with autologous cervical cancer antigen].
    Zhou CJ; Ma W; Zhou JD; Zhao YX; Xie HQ
    Ai Zheng; 2006 Feb; 25(2):143-7. PubMed ID: 16480575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Induction of T cell responses against autologous ovarian cancer by anti-idiotype minibody-pulsed dendritic cells].
    Yang WL; Cui H; Feng J; Chang XH; Fu TY; Ye X; Zhang H; Li XP; Wen HW; Feng LM; Tong CR
    Ai Zheng; 2004 Dec; 23(12):1639-45. PubMed ID: 15601552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells.
    Hoffmann TK; Meidenbauer N; Dworacki G; Kanaya H; Whiteside TL
    Cancer Res; 2000 Jul; 60(13):3542-9. PubMed ID: 10910067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
    Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Iida T; Yamaue H
    Int J Oncol; 2008 Feb; 32(2):459-66. PubMed ID: 18202769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.
    Xu JJ; Yao K; Yu CJ; Chen X; Lu MP; Sun H; Li BZ; Ding CN; Zhou F
    Auris Nasus Larynx; 2006 Dec; 33(4):441-6. PubMed ID: 16934422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.